uniQure (NASDAQ:QURE) Insider Jeannette Potts Sells 5,237 Shares

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 5,237 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the sale, the insider directly owned 133,246 shares of the company’s stock, valued at $3,686,916.82. This trade represents a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

uniQure Price Performance

NASDAQ QURE opened at $48.16 on Thursday. The company has a 50 day simple moving average of $23.55 and a 200-day simple moving average of $21.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -13.84 and a beta of 0.98. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities research analysts predict that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Militia Capital Management LLC bought a new position in shares of uniQure during the 1st quarter valued at $1,540,000. Flax Pond Capital LLC raised its holdings in uniQure by 3.8% during the first quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after buying an additional 5,533 shares in the last quarter. Stempoint Capital LP raised its holdings in uniQure by 79.5% during the first quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock valued at $1,276,000 after buying an additional 34,581 shares in the last quarter. Irenic Capital Management LP bought a new position in uniQure during the first quarter valued at about $1,635,000. Finally, Readystate Asset Management LP raised its holdings in uniQure by 39.6% during the first quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock valued at $8,252,000 after buying an additional 143,142 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now appears to support a near-term BLA submission for AMT-130, improving the odds of accelerated approval for Huntington’s disease. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight, citing the improved regulatory outlook and raising its price target to $61. Seeking Alpha
• Neutral Sentiment: The company disclosed insider sales by directors and executives, including recent transactions by Madhavan Balachandran and Jeannette Potts, which may draw attention but were executed under a pre-arranged trading plan in at least one case.
• Neutral Sentiment: Analyst opinions remain mixed overall, with recent price targets ranging widely, showing that expectations for the stock are still highly dependent on FDA and clinical execution.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on QURE. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a report on Wednesday. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Wolfe Research began coverage on uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. Stifel Nicolaus set a $28.00 price target on uniQure in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $15.00 to $60.00 in a research note on Monday, March 9th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $47.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.